Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF)
The Regenerative Clinic's view on this research
In this randomised clinical trial 57 patients with diabetes-related non-healing ulcers of the foot were treated with micro-fragmented adipose tissue (MFAT) injections, obtain. ed using the Lipogems system, at the injury site following forefoot or toe amputation. A further 57 patients were treated only with the gold standard conventional therapy following similar amputations. After 6 months, only 46% of the control group showed a fully healed wound whilst 80% of the Lipogems treated group recovered. No adverse events were recorded in the Lipogems treatment cohort. This study indicates that MFAT may have a valuable clinical application in supporting the safe natural and effective repair of complex or difficult to heal wounds.